[HTML][HTML] norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Background & Aim Primary sclerosing cholangitis (PSC) represents a devastating bile duct
disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA)
is a side chain-shortened C 23 homologue of UDCA and has shown potent anti-cholestatic,
anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A
randomized controlled trial, including 38 centers from 12 European countries, evaluated the
safety and efficacy of three doses of oral norUDCA (500 mg/d, 1,000 mg/d or 1,500 mg/d) …
disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA)
is a side chain-shortened C 23 homologue of UDCA and has shown potent anti-cholestatic,
anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A
randomized controlled trial, including 38 centers from 12 European countries, evaluated the
safety and efficacy of three doses of oral norUDCA (500 mg/d, 1,000 mg/d or 1,500 mg/d) …
